Lv4
580 积分 2024-11-27 加入
Nanobody-drug conjugates as versatile tools for improving therapeutic potential
3天前
已完结
Thrombotic thrombocytopenic purpura in caplacizumab era – An individualized approach
14天前
已关闭
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment
25天前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
1个月前
已完结
Glypican-3 Expression in Primary and Recurrent Ovarian Carcinomas
2个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
2个月前
已完结
Section 8: Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes
5个月前
已关闭
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
5个月前
已完结
Anovel anti-B7-H3 nanobody and its DM1 conjugate with marked anti-tumor activity against esophageal squamous cell carcinoma
5个月前
已完结
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
6个月前
已完结
皖公网安备34019202002308
